Skip to content
Femasys Logo
Main Menu
  • Corporate
    • About Femasys
      • Who we are
      • Leadership
    • Investor Relations
      • Overview
      • News
      • Events & Presentations
      • Stock Info
      • Financials
      • Governance
      • Resources
    • Resources
    • Contact Us
      • Contact Femasys
      • Join Us
  • Healthcare Professionals
    • Infertility
      • FemaSeed
      • FemVue
    • Birth Control
    • Cancer Diagnosis
  • Patients
    • Infertility
      • FemVue
      • FemaSeed
    • Birth Control
    • Cancer Diagnosis

Tag: GlobeNewswire

Femasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial Growth

Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update

Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors

Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment

Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Femasys Announces FemBloc® Permanent Birth Control Has Achieved MDSAP Certification, Advancing Global Market Access

Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination

Femasys Expands European Commercial Footprint with Swiss Partner for FemBloc, FemaSeed, and Portfolio Products

Femasys Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care

← older
About Femasys
  • Who We Are
  • Leadership
Investor Relations
  • Overview
  • News
  • Event & Presentations
  • Stock Info
  • Financials
  • Governance
  • Resources
Resources
  • Who We Are
  • Leadership
Contact Us
  • Contact Femasys
  • Join Us
Healthcare Professionals
  • Infertility
  • Birth Control
  • Cancer Diagnosis
Patients
  • Infertility
  • Birth Control
  • Cancer Diagnosis
Privacy Policy
Terms of Use
Patents
Accessibility
Order
Copyright © 2024 Femasys Inc.
FemaSeed, FemBloc, FemCath, FemCerv, and FemVue are registered trademarks of Femasys Inc.
Main Menu
  • Corporate
    • About Femasys
      • Who we are
      • Leadership
    • Investor Relations
      • Overview
      • News
      • Events & Presentations
      • Stock Info
      • Financials
      • Governance
      • Resources
    • Resources
    • Contact Us
      • Contact Femasys
      • Join Us
  • Healthcare Professionals
    • Infertility
      • FemaSeed
      • FemVue
    • Birth Control
    • Cancer Diagnosis
  • Patients
    • Infertility
      • FemVue
      • FemaSeed
    • Birth Control
    • Cancer Diagnosis